Organisation paid for research Program year 2024 Source: CMS Open Payments

Advantage Clinical Trial Corp

Neither a doctor nor a teaching hospital

Research payments

$22,203

11 payments

Through program year 2024, Advantage Clinical Trial Corp is reported as receiving $22,203 in research payments, across 11 payments.

By program year

4 rows

Year	Kind	Amount	Payments
2024	Research	$1,085	1
2023	Research	$729	1
2022	Research	$2,821	1
2019	Research	$17,568	8

Breakdown

Who paid Research payments · program years 2019–2024

Boehringer Ingelheim Pharmaceuticals, Inc. $10,021 2 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $8,565 4 payments
Boehringer Ingelheim International GmbH $1,814 2 payments
GlaxoSmithKline, LLC. $1,564 1 payment
Boehringer Ingelheim France S.A.S. $239 2 payments

Studies the money was for Research payments · program years 2019–2024

52 wks Eff. & Saf. Ph III in Paediatrics $18,825 8 payments
Rota-090 $1,564 1 payment
Speso moderate to severe HS Phase IIb/III $1,085 1 payment
Speso moderate to severe HS Phase IIb III $729 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.